ArticleEJHaem2020
Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience.
Article in EJHaem, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- COVID-19 outcomes among patients with sickle cell disease or sickle cell trait compared to the general population: a systematic review and meta-analyses.Annals of hematology · 2024Pooled it
- Impact of the SARS-CoV-2 infection in individuals with sickle cell disease: an integrative review.Frontiers in medicine · 2023Pooled it
- Role of Serum Ferritin in Predicting Outcomes of COVID-19 Infection Among Sickle Cell Disease Patients: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2022Pooled it
- COVID-19 outcomes in patients with sickle cell disease and sickle cell trait compared with individuals without sickle cell disease or trait: a systematic review and meta-analysis.EClinicalMedicine · 2023Article
- COVID-19 and Sickle Cell Disease: Two Independent Risk Factors for Venous Thromboembolism.Cureus · 2023Review
- Clinical and laboratory differences between pediatric hospitalized patients with sickle cell disease infected or not by SARS-CoV-2.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2023Article
- Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature.Blood reviews · 2022Review
- [SARS-CoV-2 infection in patients with sickle cell disease].Medicina clinica · 2021Article
- SARS-CoV-2 infection in patients with sickle cell disease.Medicina clinica (English ed.) · 2021Article
- The Use of Hydroxyurea in the Treatment of COVID-19.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2021Article
- Sickle cell disease and COVID-19: Susceptibility and severity.Pediatric blood & cancer · 2021Review
- Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease.Blood advances · 2021Article
- Article
- Clinical presentations and outcomes of COVID-19 infection in sickle cell disease patients: Case series from Komfo Anokye teaching hospital, Ghana.Clinical case reports · 2021Article
- The role of red blood cell exchange in sickle cell disease in patient with COVID-19 infection and pulmonary infiltrates.Clinical case reports · 2021Article
- Low morbidity and mortality with COVID-19 in sickle cell disease: A single center experience.EJHaem · 2020Article
- Article
- Low iron mitigates viral survival: insights from evolution, genetics, and pandemics-a review of current hypothesis.The Egyptian journal of medical human genetics · 2020Review
- Coronavirus disease 2019 (COVID-19) in special groups: A single-center experience in sickle cell disease patients in Saudi Arabia.Journal of family & community medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 infection, which evolved into a global pandemic within a short time. Individuals with sickle cell disease (SCD) suffer from underlying cardiopulmonary comorbidities and are at risk of severe complications such as pneumonia, acute chest syndrome, thrombosis, stroke, and multiorgan failure. Whether COVID-19 poses a high risk of morbidity and mortality in SCD patients remains unclear. Patients with SCD and COVID-19 can present with overlapping clinical features such as respiratory symptoms with ground-glass infiltrates, hyperinflammatory state, and increased risk of thromboembolism. This highlights the need to maintain a low threshold for testing for COVID-19 infection among symptomatic and hospitalized SCD patients. We report a case series of nine hospitalized SCD patients diagnosed with COVID-19 from March 18, 2020 to April 30, 2020 at a tertiary medical center in New York City. The mean age of the study population was 27.9 years, and interval since onset of symptoms and hospital presentation was 1-2 weeks. All patients in our series improved and were discharged home. This limited study shows that SCD patients, who are perceived to be high risk, maybe somehow protected from severe symptoms and complications of COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.